StemCell Therapy

Stem Cells: Revolutionizing the Treatments of Human Diseases
Stem Cells: Revolutionizing the Treatments of Human Diseases, recorded November 7, 2012. Topics Covered: Stem Cells, Developmental Biology, Research For more information and access to courses, lectures, and teaching material, please visit the official UC Irvine OpenCourseWare website at: ocw.uci.eduFrom:UCIrvineOCWViews:2 0ratingsTime:47:25More inEducation

See the original post:
Stem Cells: Revolutionizing the Treatments of Human Diseases - Video

What Are Stem Cells and their Benefits?
http://www.lami9cares.comFrom:Lami9CanadaViews:0 0ratingsTime:06:15More inPeople Blogs

Read the original:
What Are Stem Cells and their Benefits? - Video

Adult Stem Cells Not Embryonic Repair and Renew your Body
http://www.stemcelldetails4u.blogspot.inFrom:Nagarajan GViews:0 0ratingsTime:02:09More inScience Technology

View original post here:
Adult Stem Cells Not Embryonic Repair and Renew your Body - Video

Pluristem Therapeutics Inc. (PSTI) said a second of the three patients given the companys experimental stem cells has died after Pluristem touted the treatments as life-saving.

Pluristem shares soared after the Haifa, Israel-based company issued news releases in May, August and September announcing the treatments. Pluristem raised $34 million in a share sale in September without announcing that the first of those patients, a 7-year-old girl with a bone-marrow disease, had died. The company issued a press release today acknowledging the death of a second patient, though it wouldnt say when the death occurred.

Pluristem sank the most in 21 months in Nasdaq Stock Market trading yesterday after Bloomberg News reported Pluristem hadnt disclosed the girls death before the share sale. The company said today it wasnt aware of her death at the time of the offering.

The pediatric patient referred to in the Bloomberg article survived for six months, another patient survived for four months, and the third is still alive, the company said in todays statement. Pluristem believes that these results exceeded longevity expectations. The unfortunate deaths of the patients do not diminish these results.

The May 9 announcement of the girls treatment was headlined, Compassionate Use of Pluristems PLX Cells Saves the Life of a Child After Bone Marrow Transplantation Failure. On Aug. 6, the company said the cells had been administered to a 54-year-old woman with cancer suffering from bone-marrow failure. Pluristem quoted her doctor in the news release describing her subsequent recovery as a medical miracle. On Sept. 9, the company said a 45-year-old man with leukemia had received a life-saving treatment with the cells.

A spokeswoman for Pluristem declined to say today whether it was the 54-year-old woman or the 45-year-old man who had died, or provide any details about the death.

Pluristems announcements helped lift the stock from its 2012 low of $2.02 in March to an intraday high of $5 on Aug. 17.

Such press releases risk misleading investors by creating overly optimistic account of scientific research, Leigh Turner, an associate professor at the University of Minnesota Center for Bioethics, said in a blog posting yesterday. More importantly, press releases describing miracles and life-saving cures are harmful because they give seriously ill individuals an unrealistic account of effectiveness of experimental stem cell interventions.

The stock plunged after the company announced on Sept. 12 that it planned to sell shares to raise money for research expenses. Pluristem completed the sale Sept. 19. The girl died Sept. 12, a company spokeswoman said last month.

Pluristem didnt announce the girls death because it stopped following her progress after she left the hospital, Chief Executive Officer Zami Aberman said in an interview last month. She had been critically ill, and her death was unrelated to the stem-cell treatment, the company said in todays statement. Pluristem learned of her death at the discretion of her family and physician in her home country of Romania after the stock sale, the company said.

Read more:
Pluristem: Second Patient With ‘Life-Saving’ Cells Died

Every week in his clinic at the University of Michigan, neurologist Joseph Corey, M.D., Ph.D., treats patients whose nerves are dying or shrinking due to disease or injury. He sees the pain, the loss of ability and the other effects that nerve-destroying conditions cause - and wishes he could give patients more effective treatments than what's available, or regenerate their nerves.

Then he heads to his research lab at the VA Ann Arbor Healthcare System, where his team is working toward that exact goal.

In new research published in several recent papers, Corey and his colleagues from the U-M Medical School, VAAAHS and the University of California, San Francisco report success in developing polymer nanofiber technologies for understanding how nerves form, why they don't reconnect after injury, and what can be done to prevent or slow damage.

Using polymer nanofibers thinner than human hairs as scaffolds, researchers coaxed a particular type of brain cell to wrap around nanofibers that mimic the shape and size of nerves found in the body.

They've even managed to encourage the process of myelination - the formation of a protective coating that guards larger nerve fibers from damage. They began to see multiple concentric layers of the protective substance called myelin start to form, just as they do in the body. Together with the laboratory team of their collaborator Jonah Chan at UCSF, the authors reported the findings in Nature Methods.

The research involves oligodendrocytes, which are the supporting actors to neurons - the "stars" of the central nervous system. Without oligodendrocytes, central nervous system neurons can't effectively transmit the electrical signals that control everything from muscle movement to brain function.

Oligodendrocytes are the type of cells typically affected by multiple sclerosis, and loss of myelin is a hallmark of that debilitating disease.

The researchers have also determined the optimum diameter for the nanofibers to support this process - giving important new clues to answer the question of why some nerves are myelinated and some aren't.

While they haven't yet created fully functioning "nerves in a dish," the researchers believe their work offers a new way to study nerves and test treatment possibilities. Corey, an assistant professor of neurology and biomedical engineering at the U-M Medical School and researcher in the VA Geriatrics Research, Education and Clinical Center, explains that the thin fibers are crucial for the success of the work.

"If it's about the same length and diameter as a neuron, the nerve cells follow it and their shape and location conform to it," he says. "Essentially, these fibers are the same size as a neuron."

Original post:
Stem cells and nanofibers stimulating nerve research

EASTERN SHORE, Md. (WJZ) The miracle of stem cells changes the life of a little boy from the Eastern Shore.

Adam May has the amazing story of a mother and the choice she made moments after her son was born.

Xander McKinley was a beautiful babybut challenging. The newborn didnt eat or sleep well, and by two-years-old, he couldnt walk or even crawl.

Something just wasnt right, said Xanders mother, Jennifer McKinley.

Jennifer McKinley got the news every parent fears. Xander had cerebral palsya brain condition that slows motor functions.

Adam: Did you ever fear he would never have a normal life? Jennifer: We thought he wasnt going to be able to walk. It was heart-wrenching, that we knew this was permanent.

Turns out, it wasnt permanent. That young boy frustrated by immobility can now stand on his own, and even take a few stepsafter a groundbreaking experimental stem cell transfusion.

Adam: Arent you walking better now? Xander: Yeah. Adam: How good does that feel? Xander: Great!

The 6-year-old can finally climb a fence with his brother.

Adam: Youre so fast now. Xander: Yeah!

Original post:
Stem Cells Help Md. Boy With Cerebral Palsy To Walk

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Verastem, Inc., (VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, reported new data from its focal adhesion kinase (FAK) inhibition program and commented on encouraging clinical data on FAK inhibition presented at the 2012 EORTC Symposium on Molecular Targets and Cancer Therapeutics being held in Dublin, Ireland.

Data presented by Verastem in breast cancer models lacking the tumor suppressor Merlin demonstrate that FAK inhibition effectively reduces cancer stem cells in vitro and in vivo. Oral administration of a FAK inhibitor as a single agent was shown to induce tumor regression in a Merlin-negative breast cancer mouse model. These data extend previous research from Verastem, which demonstrated similar inhibition of cancer stem cells and strong single agent efficacy in Merlin-negative mesothelioma models.

Several groups presented data at the conference on the use of FAK inhibitors for treatment of cancer. In one clinical study by GlaxoSmithKline, researchers demonstrated that Merlin loss may identify a subset of patients with improved progression free survival in response to FAK inhibition. These results provide important clinical validation of our internal research demonstrating enhanced sensitivity of Merlin-negative mesothelioma to FAK inhibitors, said Jonathan Pachter, Ph.D., Verastem Vice President and Head of Research.

Verastem anticipates initiating a potentially pivotal study in mesothelioma midyear 2013.

The sum of the data on development of FAK inhibitors presented at this conference is very promising, said Professor Dean Fennell, Chair of Thoracic Medical Oncology, University of Leicester. In particular, GSK reported in a Phase 1 trial novel activity of a FAK inhibitor in mesothelioma, where treatment in the second and third-line setting resulted in a median progression free survival of 17.7 weeks.

The largest clinical trial to date in malignant pleural mesothelioma was a 2011 Phase 3 study of Zolinza as a second- and third-line treatment conducted by Merck in 660 patients. In this study, a median progression free survival of only 6 weeks was observed.

Interestingly, loss of the tumor suppressor Merlin correlated with increased clinical sensitivity to FAK inhibition, Prof. Fennell continued. A subset of patients with Merlin negative mesothelioma had more than double the median progression free survival of 24.1 weeks versus 11.4 weeks for the Merlin positive group. These early results suggest that a targeted therapy, particularly when used in combination with a specific biomarker, has the potential to significantly improve treatment of this aggressive and deadly disease.

We are encouraged by the initial clinical data presented today by GSK, said Dr. Joanna Horobin, Verastem Chief Medical Officer. Merlin loss occurs in approximately 50% of mesothelioma patients and we believe that VS-6063 has potential as a targeted therapy in this disease. We are moving rapidly to initiate a potentially pivotal, double blind controlled study next year.

FAK is a cytoplasmic tyrosine kinase that mediates signal transduction by integrins and growth factor receptors. FAK has been implicated in different steps of tumor development including tumor initiation, growth, angiogenesis and metastasis. Verastem has pioneered research on FAK as a critical regulator of cancer stem cells using technology developed by cofounder and chair of the Scientific Advisory Board, Robert Weinberg, Ph.D.

Visit link:
Verastem Reports Data on Focal Adhesion Kinase Program at the 2012 EORTC Symposium on Molecular Targets and Cancer ...

A small study suggests that stem cells from a stranger may be as good as a patient's own in undoing the damage after a heart attack has weakened the heart's ability to pump blood.

Shutterstock

Enlarge photo

A small study suggests that stem cells from a stranger may be as good as a patient's own in undoing the damage after a heart attack has weakened the heart's ability to pump blood. The study hints at the possibility that stem cells could be banked, much like blood is banked, to deal with a medical emergency in this case, heart attack.

The findings on the study of a kind of stem cell called mesenchymal cells were presented at the annual meeting of the American Heart Association this week and published online in the Journal of the American Medical Association.

"We believe the basic message of the study is that this procedure is safe and that future, larger studies are warranted," lead author Dr. Joshua Hare, director of the Interdisciplinary Stem Cell Institute at the University of Miami, told reporters at a national briefing.

The researchers studied patients following heart-attacked-caused ischemic cardiomyopathy, the most common cause of heart failure. According to the Texas Heart Institute, it occurs when the heart suffers a temporary blood shortage, resulting in loss or weakening of heart muscle tissue and reduction in its ability to pump blood.

Whether a donor's cells will work as well is important, because it can take up to two months to grow millions of cells needed for transplant and there's no time in the immediate wake of a heart attack, Stephanie Dimmeler, molecular cardiology section chief at University of Frankfurt in Germany, told U.S. News and World Reports' HealthDay. Dimmeler was not involved in the study.

For the study, researchers looked at 30 patients from Miami who had enlarged hearts that had been damaged by an earlier heart attack. Half received their own mesenchymal stem cells, while the other half received the same kind of cell, but from young, healthy donors. The heart patients each received 20 million, 100 million or 200 million stem cells into 10 scarred left ventricular sites. The researchers then followed their cases for 13 months.

Mesenchymal stem cells are taken from bone marrow and lack a feature on their surface that triggers an immune response called rejection, Hare told the Associated Press. They are multipotent cells that can change to become a number of different types of cells, including bone, muscle, ligament, cartilage, fat and tendon, according to mesenchymalcells.org, which is dedicated to providing information about that particular type of cell. The heart is a muscle tasked with pumping blood throughout the body.

See the rest here:
Study says stem cells — even a stranger's — may repair heart attack damage

ScienceDaily (Nov. 8, 2012) Canadian and Italian stem cell researchers have discovered a new "master control gene" for human blood stem cells and found that manipulating its levels could potentially create a way to expand these cells for clinical use.

The findings, published today online ahead of print in Cell Stem Cell, usher in a new paradigm for the regulation of human blood stem cells, says co-principal investigator Dr. John Dick, who holds a Canada Research Chair in Stem Cell Biology and is a Senior Scientist at University Health Network's McEwen Centre for Regenerative Medicine and Ontario Cancer Institute (OCI), the research arm of the Princess Margaret Cancer Centre. He is also a Professor in the Department of Molecular Genetics, University of Toronto.

"For the first time in human blood stem cells, we have established that a new class of non-coding RNA called miRNA represents a new tactic for manipulating these cells, which opens the door to expanding them for therapeutic uses," says Dr. Dick.

In 2011, Dr. Dick isolated a human blood stem cell in its purest form -- as a single stem cell capable of regenerating the entire blood system -- paving the way for clinical uses. He also pioneered the cancer stem cell field by identifying leukemia stem cells in 1994 and colon cancer stem cells in 2007.

OCI lead author Dr. Eric Lechman says the research team removed a master control gene -- microRNA 126 (miR-126) -- that normally governs the expression of hundreds of other genes by keeping them silenced, which in turn keeps the stem cells in a non-dividing dormant state. The method was to introduce excess numbers of miR-126 binding sites into the stem cells by using a specially designed viral vector.

"The virus acted like a sponge and mopped up the specific miRNA in the cells. This enabled the expression of normally repressed genes to become prominent, after which we observed a long-term expansion of the blood stem cells without exhaustion or malignant transformation," says Dr. Lechman.

Adds Dr. Dick: "We've shown that if you remove the miRNA you can expand the stem cells while keeping their identity intact. That's the key to long-term stem cell expansion for use with patients." The co-principal investigator was Dr. Luigi Naldini, Director, of the San Raffaele Telethon Institute for Gene Therapy, Milan.

Dr. Dick's research was funded by the Canadian Institutes of Health Research, the Canadian Cancer Society, the Terry Fox Foundation, Genome Canada through the Ontario Genomics Institute, the Ontario Institute for Cancer Research, the Canada Research Chair Program, the Ontario Ministry of Health and Long-Term Care, the Canada Foundation of Innovation, as well as The Princess Margaret Cancer Foundation.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

View original post here:
Stem cell scientists discover potential way to expand cells for use with patients

DUBLIN--(BUSINESS WIRE)--

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced multiple presentations of clinical data on its Anti-Notch2/3 and demcizumab programs at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland. Phase I clinical data on Anti-Notch2/3 were featured in an oral plenary session and additional clinical biomarker data were presented in a poster session. Demcizumab Phase Ib clinical data in non-small cell lung cancer patients were also featured in a separate poster session.

Anti-Notch2/3 (OMP-59R5)

The oral presentation, A First-in-Human Phase I Study to Evaluate the Fully Human Monoclonal Antibody OMP-59R5 (anti-Notch2/3) Administered Intravenously to Patients with Advance Solid Tumors (abstract #28), was presented by Principal Investigator David C. Smith, Professor of Medicine and Urology and the University of Michigan Cancer Center. In the clinical trial (n=39 patients), OMP-59R5 was generally well tolerated, with diarrhea as the main treatment-related and dose-related adverse event. Maximum tolerated doses (MTDs) have been established at doses of 2.5mg/kg weekly and 7.5mg/kg every three weeks. An every two week dosing schedule is also under investigation. Prolonged stable disease was noted in multiple tumor types, including adenoid cystic carcinoma, liposarcoma, Kaposis sarcoma, rectal cancer, and triple-negative breast cancer. Based on these data, OncoMed has advanced Anti-Notch2/3 into an ongoing Phase Ib/II ALPINE trial (Antibody therapy in first-Line Pancreatic cancer Investigating anti-Notch Efficacy and safety) in first-line advanced pancreatic cancer patients.

In addition, the company presented a poster (Abstract #314, Poster #64) describing the results of a comprehensive biomarker analysis in the Anti-Notch2/3 Phase 1 study, which demonstrated pharmacodynamic (PD) modulation of the Notch pathway in patients with advanced solid tumors. Principal Investigator Dr. Anthony Tolcher and colleagues of The START Center for Cancer Care, San Antonio, TX concluded that the PD effects of OMP-59R5 on Notch targets, stem cell pathways in surrogate tissues, and in tumor tissue on serial biopsy were clearly established in this first-in-human study at doses equal to or greater than 1mg/kg every other week.

Demcizumab (Anti-DLL4, OMP-21M18)

Interim Phase Ib clinical data in non-small cell lung cancer was presented in a poster session (Abstract #598, Poster #169) at the meeting. Principal Investigator Dr. Mark McKeage of the University of Auckland, Auckland, New Zealand and colleagues reported that in 17 evaluable patients, treatment of demcizumab plus pemetrexed and carboplatin resulted in disease control (partial response plus stable disease by RECIST) in 94% (16 of 17) of patients, including a 44% RECIST partial response rate. Additionally, two patients treated with 5mg/kg every three weeks remain progression free for greater than 16 months. Demcizumab was well tolerated, with fatigue and hypertension being the most common drug-related toxicities. Importantly, no patients experienced significant left ventricular ejection fraction declines or clinical congestive heart failure, which indicates that OncoMeds cardiovascular risk mitigation plan was effective in this trial. Based on this data, OncoMed believes further development of demcizumab in non-small cell lung cancer is warranted.

Both demcizumab and Anti-Notch2/3 appear to have tolerable safety profiles, and we are encouraged by the efficacy and biomarker results to date, noted Jakob Dupont, MD, OncoMeds Chief Medical Officer.

Paul Hastings, President and Chief Executive Officer of OncoMed, added, We are excited to present clinical data on two of our anti-cancer stem cell investigational product candidates at the EORTC-AACR-NCI meeting, and we look forward to advancing both of these product candidates further in clinical development.

About OMP-59R5

View post:
OncoMed Pharmaceuticals Announces Presentations of Anti-Notch2/3 and Demcizumab Clinical Data at EORTC-NCI-AACR Meeting

Integrating History And Philosophy Of Science
ll4.me Integrating History And Philosophy Of Science From the contents: Introduction by Seymour Mauskopf and Tad Schmaltz Part I: General Reflections Thomas Kuhn and Interdisciplinary Conversation: Why Historians and Philosophers of Science Stopped Talking to One Another , Jan Golinski The History and Philosophy of Science History, David M. Miller What in Truth Divides Historians and Philosophers of Science?, Kenneth Caneva History and Philosophy of Science: Recollections and Reflections, Ronald Giere Philosophy of Science and Its Historical Reconstructions , Peter Dear The Underdetermination Debate: How Lack of History Leads to Bad Philosophy, Wolfgang Pietsch Part II: Case Studies Beyond Case Studies: History as Philosophy, Hasok Chang Hidden Entities and Experimental Practice: Renewing the Dialogue between History and Philosophy of Science, Theodore Arabatzis Studying Methodological Thought: S. Weir Mitchell s Research on the Venom of Poisonous Snake, Jutta Schickore Quantum Gravity: History, Historiography and Philosophy, Dean Rickles Social Epistemology of Stem Cell Research: History, Philosophy and Experiment, Melinda Fagan History and Philosophy of Science at Work: Making Regenerative Medicine Better EAN/ISBN : 9789400717459 Publisher(s): Springer, Berlin, Springer Netherlands Discussed keywords: Geschichtsschreibung, Interdisziplinaritt, Wissenschaftsphilosophie Format: ePub/PDF Author(s): Mauskopf, Seymour - Schmaltz, Tad From the contents: Introduction by ...From:susanbranch9865Views:0 0ratingsTime:00:16More inPeople Blogs

Read more:
Integrating History And Philosophy Of Science - Video

CombiCult® Workflow
A overview on how Plasticell (www.plasticell.co.uk) uses combinatorial cell culture (CombiCult®) to discover optimised stem cell differentiation protocols in record time, at a fraction of the cost of the status quo while reducing project return risk. CombiCult® is used by our customers in a range of applications in regenerative medicine, cell therapy and research and development.From:PlasticellLimitedViews:1 0ratingsTime:06:40More inScience Technology

Read more:
CombiCult® Workflow - Video

stem cell banking | Knowing More About Cord Blood Banking
http://www.cordbloodrecommendation.com The umbilical cord blood is rich in stem cells as the baby #39;s organs, tissues and body is developed by it. Diseases that are genetically based would most likely be an allogenic transplant. Human umbilical cord blood cells are very rich in stem cells and progenitor cells which make them the perfect place to take cells from and then store them in a cord blood bank or a stem cells bank. There is also another option given by non-profit cord blood banks, of free programs through which one can store umbilical cord blood stem cell samples. A man can change his god-gifted features wishfully with the help of science. Given the progress that stem cell research and regenerative medicine have attained at present, and the promise that they show for the future, stem cell transplants may one day provide a cure for type 1 diabetes, heart disease, and brain injury, among other potentially life threatening and debilitating illnesses and conditions with inadequate treatment options today. One study in particular by Wagner, et al. ""The theory exists that any reduction in the volume of umbilical cord blood units in albumin or dextran prior to transfusing into patients leads to better cell viability. The mother will be informed about the status of the blood unit and the test results so that she is aware of any infection or disease that might affect her baby. Many parents see placental and cord blood banking as valuable tools to help them secure potentially ...From:fivespanishViews:0 0ratingsTime:01:18More inScience Technology

The rest is here:
stem cell banking | Knowing More About Cord Blood Banking - Video

cryocell | Why Store Your Cord Blood In a Bank?
http://www.cordbloodrecommendation.com A large number of people die waiting for a transplant due to this reason. Before any blood donations are made it is important for a pregnant mother interested to make the donation to contact the bank before the thirty fourth week of her pregnancy. However, private banking is generally not recommended unless there is a family history of specific genetic diseases. It contains stem cells that have been found to be excellent for research and treatment of many diseases. A man can change his god-gifted features wishfully with the help of science. Given the progress that stem cell research and regenerative medicine have attained at present, and the promise that they show for the future, stem cell transplants may one day provide a cure for type 1 diabetes, heart disease, and brain injury, among other potentially life threatening and debilitating illnesses and conditions with inadequate treatment options today. One study in particular by Wagner, et al. ""Settling on a name for your newborn is definitely something all parents spend time doing, but one decision that is rarely thought of or overlooked is saving your newborn #39;s cord blood. The mother will be informed about the status of the blood unit and the test results so that she is aware of any infection or disease that might affect her baby. Many parents see placental and cord blood banking as valuable tools to help them secure potentially lifesaving treatment options their families may some day ...From:loshoteles enmedellinViews:0 0ratingsTime:01:18More inScience Technology

View post:
cryocell | Why Store Your Cord Blood In a Bank? - Video

PHILADELPHIA As researchers work on reconfiguring cells to take on new regenerative properties, a new review from Penn Medicine plastic surgeons sheds additional light on the potential power of adipose-derived stem cells - or adult stem cells harvested from fatty tissue - in reconstructive and regenerative medicine.

Reconstructive plastic surgeons have clinically integrated "fat grafting" into different surgeries for years, for breast, facial, and other reconstructive and restorative surgeries, with good success. Now, researchers are beginning to understand the power that fatty tissue holds. This new paper, published in the Aesthetic Surgery Journal, enforces that adipose-derived stem cells can be routinely isolated from patients and, once molecular methods are worked out, may be useful for a multitude of regenerative medicine applications.

"The opportunities for regenerative medicine interventions based on adult stem cells are tremendous. It is critically important for us to better understand the biology of these cells so that we can develop novel, safe and effective treatments for our patients using their own cells." said the paper's senior author, Ivona Percec, MD, PhD, assistant professor in the division of Plastic Surgery in the Perelman School of Medicine at the University of Pennsylvania.

Many groups are looking into different modes of isolating and modifying these cells for their regenerative properties, including experts at Penn's Institute for Regenerative Medicine and around Penn Medicine. For example, Dr. Percec's team is conducting translational research into the mechanisms controlling adipose-derived stem cells, and how they contribute to the normal human aging process.

Stem cells can undergo multiple divisions without differentiation, making them useful tools for cell-replacement therapy. Embryonic stem cells can convert to any cell type, whereas adult stem cells, like the stem cells derived from fat, can differentiate into many, but not all, cell types. A person's own fat tissue could then potentially be converted into cells specially designed to repair damage to the heart, cartilage, blood vessels, brain, muscle, or bone.

As regenerative medicine techniques are refined, experts will continue to explore the utility and benefits of stem cells derived from adipose tissue.

The Perelman School of Medicine is currently ranked #2 in U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $479.3 million awarded in the 2011 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2011, Penn Medicine provided $854 million to benefit our community.

Original post:
Fat-derived Stem Cells Hold Potential for Regenerative Medicine

CAMBRIDGE, Mass., BOSTON and NEW YORK, Nov. 8, 2012 /PRNewswire/ --GNS Healthcare, Inc. (GNS), the leading healthcare data analytics company focused on enabling personalized medicine to improve human health, today announced that it has entered into a collaboration with Dana-Farber Cancer Institute (Dana-Farber) and Mount Sinai School of Medicine (Mount Sinai) to create a data-driven computer model of multiple myeloma, the second most common blood cancer in the U.S. that constitutes approximately one percent of all cancers. Created using GNS's supercomputer-driven REFS (Reverse Engineering and Forward Simulation) platform, the models will be used to help researchers discover novel therapies for the disease and to help determine the best existing treatments for patients.

"We have made encouraging progress at Dana-Farber Cancer Institute in using gene profiling, proteomic and signaling studies in tumor cell samples treated with existing and novel medicines to get a better understanding of myeloma pathogenesis and to develop novel targeted therapies," said Dr. Ken Anderson, Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics at Dana-Farber and Kraft Family Professor of Medicine at Dana-Farber and Harvard Medical School.

"Because of this progress, our team is excited about deploying a powerful, supercomputer driven approach using our multi-layered genomic data to develop computer models to directly define the integrated underlying circuitry of myeloma. We look forward to using these models to identify, create, and implement better treatments for individual multiple myeloma patients," said Dr. Nikhil Munshi, Associate Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics at Dana-Farber and Associate Professor of Medicine, Harvard Medical School.

"GNS will apply its Big Data analytics platform to create a disease-specific computer model that will yield a powerful new resource to the multiple myeloma research and clinical communitywith the ultimate aim of better outcomes for patients," said GNS CEO and co-founder Colin Hill. "This collaboration with Dana-Farber and Mount Sinai will create models that will help transform the tremendous amount of data coming from new technologies, such as next-generation sequencing, into predictive computer models of disease progression and treatment response for scientists and clinicians. This project is one of many examples of our work in challenging, complex and, sometimes rare, diseases."

In this collaboration, GNS will employ the REFSplatform to reverse engineer network models from next-generation genetic sequencing, proteomic, outcomes and other clinical data. Results from millions ofin silico simulations of the REFS models will provide new insights into the fundamental mechanisms of multiple myeloma, enabling the identification of novel intervention points in the disease for specific groups of patients and the development of more effective medicines.

"Prior published work has shown us that approaches like the REFS platform can develop integrated network models of disease that can be used to uncover novel drivers of disease," said Dr. Eric Schadt, Director of the Institute for Genomics and Multiscale Biology, Chair of the Department of Genetics and Genomics Sciences and the Jean C. and James W. Crystal Professor of Genomics at Mount Sinai. "With the wealth of detailed biological data available in this project, we look forward to a close collaboration with GNS to build a predictive model to elucidate novel insights into this complex disease."

About Multiple Myeloma

Multiple myeloma is a cancer of plasma cells, a type of white blood cell normally responsible for producing antibodies. In multiple myeloma, collections of abnormal plasma cells accumulate in the bone marrow, where they interfere with the production of normal blood cells. Most cases of myeloma also feature the production of a paraproteinan abnormal antibody which can cause kidney problems. Bone lesions and hypercalcemia (high calcium levels) are also often encountered. Myeloma is diagnosed with blood tests (serum protein electrophoresis, serum free kappa/lambda light chain assay), bone marrow examination, urine protein electrophoresis and X-rays of commonly involved bones. Myeloma is generally thought to be treatable but incurable. Remissions may be induced with steroids, chemotherapy, proteasome inhibitors (e.g. bortezomib), immunomodulatory drugs (IMiDs) such as thalidomide or lenalidomide and stem cell transplants. Radiation therapy is sometimes used to reduce pain from bone lesions. Myeloma develops in 1-4 per 100,000 people per year. It is more common in men, and for unknown reasons is twice as common in African-Americans as it is in white Americans. With conventional treatment, median survival is 3-4 years, which may be extended to 5-7 years or longer with advanced treatments. Multiple myeloma is the second most common hematological malignancy in the U.S. (after non-Hodgkin lymphoma) and constitutes 1 percent of all cancers.

About REFS

REFS (Reverse Engineering and Forward Simulation) is GNS Healthcare's scalable, supercomputer-enabled framework for discovering new knowledge directly from data. REFS automates the discovery and extraction of causal network models from observational data and uses high-throughput simulations to generate new knowledge.

Read this article:
GNS Healthcare, Dana-Farber and Mount Sinai Collaborate to Build Computer Model of Multiple Myeloma

Dr Nathan Newman MD Stem Cell Face lift (ENHANCING YOUTH)
Jeunesse is not the same old story of skin care and supplements. We are not the same old network model. Jeunesse is a global business that helps people reach their full potential in youthful looks, in healthy living, in embracing life. Jeunesse combines breakthrough sciences in a product system that enhances youth by working at the cellular level. By focusing on the health, longevity, and renewal of cells, we help people enjoy vibrant, youthful results that last. Jeunesse delivers the rewards of youth in four innovative ways: Products. The Jeunesse Youth Enhancement System (YES) isn #39;t just about looking young. It #39;s about feeling young for the long term. Even the sciences we employ are new and cutting edge. Our best-of-the-best formulas are innovative, and the youthful results are real. Learn more about our line of Personal Care and Nutrition products. People. Jeunesse shares an emotional reward no networking company can match. The culture of Jeunesse springs from the integrity and core values of our Founders. As a result, our global family of distributors experience rewarding relationships based on mutual respect, trust, and love. Plan. With one of the most lucrative and truly balanced compensation plans around, the Jeunesse Financial Rewards Plan is able to reward more people with more money. And with the plentiful incentives and built-in travel promotions that are our way of doing business, the Jeunesse culture is in itself a rewarding lifestyle. Learn more about our ...From:paulwarioViews:0 0ratingsTime:02:48More inHowto Style

Continue reading here:
Dr Nathan Newman MD Stem Cell Face lift (ENHANCING YOUTH) - Video

Regenerative Nephrology
ll4.me Regenerative Nephrology Progression of chronic diseases in general and chronic kidney disease in particular has been traditionally viewed in the light of various contributors to development of glomerulosclerosis and tubulointerstitial scarring culminating in renal fibrosis. Indeed, this dogma prevailed for decades underscoring experimental attempts to halt fibrotic processes. Breakthrough investigations of the past few years on stem/progenitor cell involvement in organ regeneration caused a conceptual shift in tackling the mechanisms of nephrosclerosis. It has become clear that the rate of progression of chronic kidney disease is the net sum of the opposing trends: degenerative fibrotic processes and regenerative repair mechanisms. The latter part of this equation has been by and large ignored for years and only recently attracted investigative attention. This book revisits the problem of kidney disease by focusing on regenerative mechanisms in renal repair and on the ways these regenerative processes can become subverted by an intrinsic disease process eventuating in its progression. Cutting-edge investigations are summarized by the most experienced international team of experts.* Presents a comprehensive, translational source for all aspects of renal stem cells, tissue regeneration, and stem cell therapies for renal diseases in one reference work. This will ultimately result in time savings foracademic, medical and pharma researchers. * Experts in the renal stem ...From:lorraineknouse326Views:0 0ratingsTime:00:12More inPeople Blogs

See more here:
Regenerative Nephrology - Video

Immunice Recommendations
Recommendations You can boost your Immunity by: 1) Reversing Damage - Years of stressful living caused damage to your Immune System. To help reverse this, Immunice releases hundreds of phytonutrients that act at the molecular level to enhance T cell activation, improve proliferation of Lymphocytes, bone marrow cells, and Thymocytes, increase antibody, Leucocyte, Cytokine, and red blood cell production, raise mast cell levels, and stimulate Phogocytosis and plasma fibrinolytic activity in your body. 2) Exercising Regularly - Regular exercise elevates the level of leukocytes, an Immune System cell that fights infection. Exercise also increases release of endorphins, natural hormones that heighten your sense of well being and improve sleep quality, both of which have positive effects on your Immune System. Exertion stimulates the cardiovascular system, improves blood flow, circulates antibodies, flushes toxins from muscles and organs, removes germs, and helps keep the kidneys and endocrine system fully functional. Moderate exercise must be repeated on a near-daily basis so that there is a cumulative effect that leads to a long-term immune response. Getting your heart rate up for just 20 minutes three times a week is associated with increased immune function, and a 30-minute brisk walk five days a week can help reduce your risk of catching a cold. Walking strengthens your cardiovascular system and blood flow. Walk ten minutes, three times a day if you are unable to walk 30 ...From:ihholisticsViews:0 0ratingsTime:11:52More inEducation

More here:
Immunice Recommendations - Video

Post-genomic Cardiology
ll4.me Post-genomic Cardiology Recent advances in molecular and cellular biology have markedly changed our understanding of the heart, and this is having tremendous ramifications for the clinician. This unique reference offers a comprehensive and critical evaluation of this contribution in the field of cardiovascular molecular medicine providing the reader with a sense of new directions in which molecular medicine might be applied. It begins with a detailed primer that makes readily accessible recent molecular, genetic and cellular techniques. Rounding out the coverage of this exciting field are critical and comprenhesive discussions on the use of molecular, genetic and cellular techniques used to identify the etiology and pathophysiology of specific cardiac diseases.* Discusses diagnostic and therapeutic options available not only in the adult and aging individuals but also in infants/children* Numerous illustrations and flow-charts* Explans cutting-edge molecular techniques, including analysis of mitochondria, their role in cardiac dysfunction and updated analysis of Cardioprotection and Metabolic Syndrome* Presentation of recent translational studies for the treatment of cardiovascular diseases is included (eg, gene therapy, pharmacological treatments and stem cell transplantation) Publisher: Academic Press Illustration: Y Language: ENG Title: Post-Genomic Cardiology Pages: 00000 (Encrypted PDF) On Sale: 2007-02-26 SKU-13/ISBN: 9780123736987 Category: Medical ...From:julianlewis9854Views:0 0ratingsTime:00:14More inPeople Blogs

Excerpt from:
Post-genomic Cardiology - Video